参考文献/References:
[1] MAHENDRARAJ K,SHRESTHA S,LAU C S,CHAMBERLAIN R S.Ocular melanoma-when you have seen one,you have not seen them all:A clinical outcome study from the surveillance,epidemiology and end results (SEER) database (1973-2012)[J].Clin Ophthalmol,2017,11:153-160.
[2] AMARO A,GANGEMI R,PIAGGIO F,ANGELINI G,BARISIONE G,FERRINI S,et al.The biology of uveal melanoma[J].Cancer Metastasis Rev,2017,36(1):109-140.
[3] HARBOUR J W.A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile[J].Methods Mol Biol,2014,1102:427- 440.
[4] CHATTOPADHYAY C,KIM D W,GOMBOS D S,OBA J,QIN Y,WILLIAMS M D,et al.Uveal melanoma:from diagnosis to treatment and the science in between cancer[J].Cancer,2016,122(15):2299-2312.
[5] CARVAJAL R D,SCHWARTZ G K,TEZEL T,MARR B,FRANCIS J H,NATHAN P D,Metastatic disease from uveal melanoma:treatment options and prospects[J].Br J Ophthalmol,2017,101(1):38-44.
[6] JOVANOVIC P,MIHAJLOVIC M,DJORDJEVIC-JOCIC J,VLAJKOVIC S,CEKIC S,STEFANOVIC V.Ocular melanoma:An overview of the current status[J].Inter Clin Exper Patholol,2013,15,6(7):1230-1244.
[7] DAMATO B.Does ocular treatment of uveal melanoma influence survival.British[J].Cancer,2010,103(3):285-290.
[8] MAHAJAN A,CRUM A,JOHNSON M H,MATERIN M A.Ocular neoplastic disease[J].Seminars Ultrasound,CT MRI,2011,32(1):28-37.
[9] KALIKI S,SHIELDS C,SHIELDS J.Uveal melanoma:estimating prognosis[J].Int Ophthalmol,2015,63(2):93-102.
[10] KRANTZ B A,DAVE N,KOMATSUBARA K M,MARR B P,CARVAJAL R D.Uveal melanoma:epidemiology,etiology,and treatment of primary disease[J].Clin Ophthalmol,2017,11:279-289.
[11] LOGAN P,BURNIER J,BURNIER M N.Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines[J].Ecancermedicalscience,2013,7:336.
[12] FRANCIS J H,KIM J,LIN A,FOLBERG R,IYER S,ABRAMSON D H.Growth of Uveal melanoma following intravitreal bevacizumab[J].Ocul Oncol Pathol,2017,3(2):117-121.
[13] GE H,LUO H.Overview of advances in vasculogenic mimicry- a potential target for tumor therapy[J].Cancer Manag Res,2018,10:2429-2437.
[14] TRIOZZI P L,SINGH A D.Adjuvant therapy of uveal melanoma:current status[J].Ocul Oncol Pathol,2015,1:54-62.
[15] TARLAN B,KIRATLI H.Uveal melanoma:current trends in diagnosis and management[J].Turkish Ophthalmol,2016,46(3):123-137.
[16] Clinical Trials.gov.[EB/OL].[2018-05-01].http://www.clinicaltrials.gov.
[17] PEREIRA P R,ODASHIRO A N,LIM L A,MIYAMOTO C,BLANCO P L,ODASHIRO M,et al.Current and emerging treatment options for uveal melanoma[J].Clin Ophthalmol,2013,7:1669-1682.
[18] RODRGUEZ A,DUEAS-GONZALEZ A,DELGADO-PELAYO S.Clinical presentation and management of uveal melanoma[J].Mol Clin Oncol,2016,5(6),675-677.
[19] YANG J,MANSON D K,MARR B P,CARVAJAL R D.Treatment of uveal melanoma:where are we now[J]?Ther Adv Med Oncol,2018,10:1758834018757175.
[20] PAPASTEFANOU V P,COHEN V M.Uveal melanoma[J].J Skin Cancer,2011,2011:573974.
[21] OLIVA M,RULLAN A J,PIULATS J M.Uveal melanoma as a target for immune-therapy[J].Ann Tran Med,2016,4(9):172.
[22] FENG X,DEGESE M S,IGLESIAS-BARTOLOME R,VAQUE J P,MOLINOLO A A,RODRIGUES M,et al.Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry[J].Cancer Cell,2014,25(6):831-845.
[23] AVRIL M F,AAMDAL S,GROB J J,HAUSCHILD A,MOHR P,BONERANDI J J,et al.Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma.A phase Ⅲ study[J].Clin Oncol,2004,22(6):1118-1125.
[24] ZIMMER L,VAUBEL J,MOHR P,HAUSCHILD A,UTIKAL J,SIMON J,et al.Phase II DeCOG-study of Ipilimumab in pretreated and treatment-nave patients with metastatic uveal melanoma[J].PLoS One,2015,10(3):e0118564.
[25] SURRIGA O,RAJASEKHAR V K,AMBROSINI G,DOGAN Y,HUANG R,SCHWARTZ G K,et al.A c-Met inhibitor prevents metastasis in a metastatic uveal melanoma model[J].Mol Cancer Ther,2013,12(12):2817-2826.
[26] HU Z,MCMICHAEL E,CAMPBELL A,LONDON A C,CARSON E W.Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second-generation ICON[J].Imm Cancer,2015,3(Suppl 2):P304.
[27] LEYVRAZ S,PIPERNO-NEUMANN S,SUCIU S,BAURAIN J F,ZDZIENICKI M,TESTORI A,et al.Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021):A multicentric randomized trial[J].Ann Oncol,2014,25(3):742-746.
[28] BARAK V,FRENKEL S,KALICKMAN I,MANIOTIS A J,FOLBERG R,PEER J.Serum markers to detect metastatic uveal melanoma[J].In Ant Res,2007,27(4A):1897-1900.
[29] COOLS-LARTIGUE J J,MCCAULEY C S,MARSHALL J C A,CESARE S D I,GREGOIRE F,ANTECKA E,et al.Immunomagnetic isolation and in vitro expansion of human uveal melanoma cell lines[J].Mol Vis,2008,14:50-55.
[30] HERCEG Z,HAINAUT P.Genetic and epigenetic alterations as biomarkers for cancer detection,diagnosis and prognosis[J].Mol Oncol,2007,1(1):26-41.
相似文献/References:
[1]周朋义 彭广华.视网膜色素变性治疗的研究进展[J].眼科新进展,2012,32(5):000.
[2]杨红 阴正勤.眼球震颤的诊断与治疗研究进展[J].眼科新进展,2012,32(5):000.
[3]邵毅 周琼 易昀敏 余瑶 裴重刚 吴晓蓉 梅峰 占敏艳.鬼针草叶治疗非增生型糖尿病视网膜病变的临床研究[J].眼科新进展,2013,33(6):000.
[4]杨世琳 杜改萍 郝玉华.频域OCT观察Vogt-小柳-原田病患者病程中黄斑中心凹的图像特点[J].眼科新进展,2013,33(6):000.
[5]曾春梅 文勇 成旋.特发性息肉样脉络膜血管病变的治疗进展[J].眼科新进展,2013,33(7):000.
[6]蒋永强 吴晓梅.眼睑皮脂腺癌治疗的研究进展[J].眼科新进展,2008,28(9):000.
[7]李明 张永喜 王胜根.葡萄膜黑色素瘤术后自体细胞因子诱导的杀伤细胞治疗效果观察[J].眼科新进展,2012,32(8):000.
[8]王玲 郑振优 邢健强.白内障摘出联合人工晶状体植入术治疗闭角型青光眼合并白内障临床疗效分析[J].眼科新进展,2012,32(9):000.
[9]毛新帮 游志鹏 赵菊莲.应用25G经结膜无缝合玻璃体切割系统治疗特发性黄斑前膜[J].眼科新进展,2013,33(3):000.
[10]刘鑫 苏冠方 王晨光 祝伟.玻璃体切割联合眼内填充术后眼压升高的相关因素分析及治疗[J].眼科新进展,2013,33(11):000.